Mapi Pharma
Privately held: no public share price · Israel
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | Dopamine D3/D2 receptor (partial agonist)Small molecule | Schizophrenia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Cariprazine long-acting injection (Mapi Pharma)Phase 1/2Schizophrenia, Bipolar I Disorder, Major Depressive Disorder
Est. primary completion 2026-12-31 · NCT07185815 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
12 August 2026Topline resultCariprazine long-acting injection (Mapi Pharma)Cariprazine Depot Phase I/IIa Cohort 1 top-line results
Financial reports
No financial reports recorded.